CYP3A4 and tuberculosis: We recognize that rifabutin co-administration would have been a TB treatment option with less potential for DDIs than RIF, as it is a moderate CYP3A4 inducer [9, 11]; however, there were no available IV formulations of rifabutin available in the United States.